FDA rejects Avastin for breast cancer treatment

An FDA advisory panel voted yesterday not to recommend Avastin as a treatment for breast cancer. The panel, which saw on a closely-split 5-4 vote, decided that Avastin's toxic side effects outweighed the drug's ability to delay cancer worsening, particularly given that the drug didn't raise women's overall lifespan. The panel decision isn't binding--the FDA makes the final decision on approvals--but it usually follows the advice of advisory committees.

Avastin is already a very successful drug which is widely used worldwide to treat colon and lung cancer, generating $1.7 billion in revenue for the first nine months of 2007 alone. However, the advisory committee decision is still a big setback for drugmaker Genentech, which had hoped to add $1 billion annually in Avastin sales if the drug was approved for breast cancer treatment.

To learn more about the decision:
- read this piece from The New York Times

Related Articles:
FDA slams use of Avastin for breast cancer. Report
Cost of cancer drug examined. Report
Targeted therapies highlight oncology conference. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.